Industrifonden

If prevention can greatly reduce healthcare costs, why isn't it happening? An important question for all healthcare systems, but with no single simple answer. But Jonathan Ilicki touched on some key problems in a panel at Sting Day 2024. History grants perspective - We have come far. For instance, we've halved heart attack rates in just 20 years and significantly improved child mortality in past 100 years. We do have many preventative programs which are yielding great benefits. But scientific and technological progress means we can go much further and do much more. - Therein lies the challenge. Among all the increasing number possible preventive screenings or interventions, which should politicians prioritize? The earlier one goes, the more challenging the health economic validation becomes. What risk should we be ready to bear to learn about large-scale preventative measures? Where should the resources come from? It's difficult to prioritize prevention when someone is bleeding out in front of you, and several healthcare decisionmakers I've talked to have likened it to that. ➡️We need to explore novel financing mechanisms solving this, in order to find the right interventions, and enable new resources to be spent. Health bonds, e.g. like what Health Integrator is doing is a good example Decision horizon misalignment - 4-year mandate periods (vs longer) are great for democracy, but problematic for long term health initiatives, where investing in preventive measures will benefit a budget and another decisionmaker 20 years later. - This is a general problem in driving change in complex healthcare systems with interlinked actors, but especially problematic for larger preventative programs ➡️ We need ways to educate laymen on the value of preventative investments, so that courageous long-termist politicians can gain political support to invest in unsexy simple preventative programs Devious ontological watersheds - There is a fundamental issue when healthcare is translated into accounting. For example, healthcare risk factors, for example hypertension and diabetes, aren't visible in the balance sheet, which is why investments in reducing them make limited sense from a purely accounting perspective ➡️ We need novel accounting standards for health care systems, which would denote risk factors as debt, and visualize the progress of preventative interventions and thereby facilitate investments in decreasing those debts.

As part of this year’s Industrifonden Venture Summit, we recognized three outstanding companies with the Venture Summit Awards 2024. Today, we’re shining a spotlight on the winner of the Best Exit Award. A big congratulations to Calliditas Therapeutics for their successful exit this year! Led by Renee Aguiar-Lucander, Calliditas brought their lead drug, Tarpeyo, to market, addressing a major unmet medical need in kidney function preservation. With revenues of 1.2 billion SEK in 2023 and a major acquisition deal with Asahi Kasei in 2024 for 11.2 billion SEK, Calliditas has set a remarkable standard for success. Congratulations to Renee Aguiar-Lucander, Bengt Julander, and the entire Calliditas Therapeutics team on this incredible achievement!

We’re excited to see Mala Valroy take the stage at Norrsken Impact/Week for a crucial discussion on integrating social impact with business strategy on November 7. During the panel "How Impact Objectives Affect Your Fund and Business," Mala will explore how impact goals can shape businesses and funds, alongside Matt Penneycard (Ada Ventures) and Carol Rossborough (Founder, Esther). Join us for an engaging discussion on driving positive change through impact-driven investment!

The European Commission has officially launched the Trusted Investors Network, uniting 71 investors from across Europe, collectively representing over €90 billion in assets, to co-invest in innovative deep-tech companies alongside the EIC Fund. This initiative aims to accelerate the growth of Europe’s most promising startups in critical technology sectors. We at Industrifonden are excited to be part of this network, committed to driving innovation and scaling up deep-tech companies across Europe. Learn more on the link below.

At this year’s Industrifonden Venture Summit, we had the honor of presenting three awards to outstanding companies in our portfolio. Today, we’re highlighting the winner of the Strongest Value Creation award. Telness Tech, a company we invested in just two years ago, has shown exceptional progress in building an automated platform for mobile virtual network operators. Led by Martina Klingvall, Telness Tech has already secured significant deals and key customers in multiple markets, positioning itself as a challenger to legacy telecom players worldwide. Well done to Martina and the Telness Tech team for this impressive achievement!

As part of this year’s Industrifonden Venture Summit, we presented three awards to recognize exceptional achievements. This week, we will be highlighting the winners. First up, Trialbee, who received the Fast Growth Award. Since 2013, Trialbee has been transforming the clinical trials space with its innovative digital platform, addressing the critical challenges of patient recruitment and retention. Under the leadership of Matt Walz, CEO since 2020, the company has seen remarkable growth, with revenues doubling last year and projected to grow by 70% in 2024. Congratulations to Matt Walz and the entire Trialbee team for this outstanding achievement!

Last week, we hosted the second annual Industrifonden Venture Summit, where innovators, business leaders, scientists, and venture capitalists gathered in Stockholm for a day filled with forward-thinking discussions and invaluable insights. Together, we explored key trends in AI, biotech, climate tech, and navigating uncertainty in today’s rapidly evolving landscape.   Thank you to everyone who attended and contributed to making the event such a success. A special thanks to our brilliant speakers for sharing their invaluable insights. Highlights from the day included: ▶️ Anders Sandberg, Researcher and Futurist, on navigating grand uncertainties in today’s world. ▶️ Tomas Naucler, Senior Partner at McKinsey & Company, on financing climate tech and the opportunities and challenges for venture capital. ▶️ Milla Koistinaho, Founding Partner at Innovestor Life Science Fund, Susanne K. Schorsch, Partner at Amadeus Capital Partners, and Catherine Lewis La Torre, Non-Executive Director at Cumulus Oncology, on growing your capital base across geographies, moderated by Tobias Elmquist. ▶️ Martina Klingvall, Founder and CEO of Telness Group, Birgitta Stymne Göransson Göransson, Chair of Industrifonden, and Lena Olving, Chair and Board Professional, on the complexities of Chair-CEO dynamics. ▶️ Sara Öhrvall, Senior Advisor, Board Director, Investor and Author, Daniel Sack, Managing Director & Partner at BCG X, and Daniel G., Chief of AI at Recorded Future, sharing their perspectives on a future shaped by AI. ▶️ Mathias Uhlen, Professor at KTH, and Birgitta Henriques Normark, Professor at Karolinska Institutet, on the future of biotech and vaccines, moderated by Fredrik Lehmann. We look forward to continuing these conversations and building on the insights shared during the summit. Thank you to everyone who made this event a success.

We are delighted to announce that Industrifonden has made the finalist roster for the 2024 European Lifestars Awards - Celebrating Life Science Leaders Awards in the category of VC Firm of the Year. We are also pleased to see three of our portfolio companies recognized: ▶️ Minervax ApS in Late Stage Venture Fund / Series C+ ▶️ Calliditas Therapeutics in M&A of the Year ▶️ Asgard Therapeutics and Calliditas Therapeutics in Biotech of the Year We’re looking forward to the awards announcement on November 18 and are honored to be in such excellent company among the finalists.

We're happy to welcome H&M Group as a new strategic investor in Avassa, joining us and Fairpoint Capital in supporting their next chapter of growth. With this new round of funding, Avassa is well-positioned to continue driving innovation in edge computing. Congratulations to the team on this exciting milestone!

We are incredibly proud to see Jonathan Ilicki, Principal at Industrifonden, has been selected to join the prestigious Obama Foundation Leaders Europe Program. Jonathan’s impressive background in medicine, venture capital, and entrepreneurship aligns seamlessly with the Obama Foundation’s vision of fostering future leaders dedicated to creating sustainable change. At Industrifonden, we believe in supporting individuals and companies that create real societal value, and Jonathan’s selection is a fantastic recognition of his dedication to this mission. Congratulations, Jonathan! We look forward to seeing how you’ll continue to make a difference alongside this incredible group of leaders. Read more here: https://lnkd.in/dhMq3EVH